Next week could usher in the beginning of a new era as the world's biggest blockbuster drug meets biosimilar competition for the first time in Europe. Under nonexclusive licensing agreements with Abbvie Inc., of North Chicago, at least three biosimilars to Humira (adalimumab) can begin taking flight, beginning Tuesday, in the 28 member states of the EU, as well as Iceland, Lichtenstein and Norway.